Commissioned Research
Support for Vaccine Development
Principle Investigator Name
Title
Tel.:
Mobile:
Fax: E-mail:
Name of Organization
Mailing Address
Country:
Research Project
Project Title
Project Acronym (max 20 characters)
Project Summary
Total Budget Requested
In most cases, initial discussions will need to occur with service provider to estimate
budget request
Requested Access to Service (Please check)
Please be aware that all research support offered here must be applied for specifically
as needed in the context of vaccine development. For specific questions regarding the
individual services, please contact the providers directly
Adjuvants
Evaluation of potency of new exploratory adjuvants bench-marked against the established adjuvants
systemically and/or mucosally as pertain to immune-profiling and functionality of the immune response in
mice. University of Gothenburg, A. Harandi (ali.harandi@microbio.gu.se) 21,500€/adjuvant/1 full
experiment with control and bench-mark arms.
Pre-clinical QS-21 is available for use in their early vaccine formulations and GMP quality QS-21 for
human clinical trials. Desert King International (ADITEC affiliated partner), D. Hiley
(dfhiley@desertking.com).
Three independent adjuvants: sodium arsenite, gramacidine and dithiocarbonate and high
throughput template to analyse sequentially molecular interactions between any other adjuvant and
dendritic T and B cells with particular reference to the inflammasome and homeostatic pathways leading to
immunological memory. King’s College of London, T. Lehner (thomas.lehner@kcl.ac.uk).
CAF01 adjuvant for preclinical and clinical testing: 1) CAF01 is offered for free for preclinical
evaluation with the limitation that an MTA has to be negotiated. And We can offer GMP quality CAF01 upon
contract and price negotiation. Statens Serum Institut, Dennis Christensen (DEN@ssi.dk)
Animal models
Mouse Model: University of Siena, D Medaglini (Medaglini@unisi.it)
Perform pre-clinical studies in the mouse model to assess the immunogenicity of vaccine formulations and
prime-boost strategies.
Chlamydia Challenge Mouse Model: Statens Serum Institut, Frank Follmann (FRF@ssi.dk)
Perform immunogenicity analysis and challenge experiment in the Chlamydia mouse model.
Immunogenicity + Challenge of a group of 12 mice. The prize includes control groups (negative / positive).
12.000€ / vaccine group (of 10 mice) up to 4 groups.
TB Challenge Mouse Model: Statens Serum Institut, Else Marie Agger (EAG@ssi.dk)
Perform immunogenicity analysis and challenge experiment in the TB mouse model. Immunogenicity +
Challenge of a group of 10 mice. The prize includes control groups (negative / positive). 10.000€ / vaccine
group (of 10 mice) up to 4 goups
Influenza Challenge Mouse Model: Imperial College London, J Tregoning
(john.tregoning@imperial.ac.uk)
Perform influenza challenge models following immunisation. Immunisation can be by various routes, both
mucosal and systemic. Infection can be with H1N1, H3N2 or B strains, enabling homologous or
heterologous infection and protection assessed by disease and viral load measurements. Assess
immunogenicity in the same animals – both antibody and cellular. N=5 mice per group, max 6 groups per
study.
Non-Human Primate Model: CEA, Immuno-Virology & IDMIT infrastructure, R.LeGrand
(roger.le-grand@cea.fr)
NHP models for HIV, Flu, Chicungunya virus, Dengue, Chlamydia, Malaria Immuno-monitoring core : Flow
Cytometry, Mass Cytometry (CyTof) In vivo imaging
Human Trials
Human Challenge Models for Typhoid and parathyphoid vaccination/infection
University of Oxford, A. Pollard (andrew.pollard@paediatrics.ox.ac.uk).
Human Trials (including infants) for systems immunology to study transcriptome, B/T cell
immunology University of Oxford, A. Pollard (andrew.pollard@paediatrics.ox.ac.uk).
Clinical trial support from concept through to completion. Services can include:
protocol design and review, regulatory submissions and approvals, sponsorship of clinical trials, project
management of trial, pharmacovigilance and monitoring support, clinical trial delivery ,laboratory
processing of samples, data management, statistical analysis and clinical study reporting. Surrey Clinical
Research Centre, D. Lewis (D.J.Lewis@surrey.ac.uk)
MLPA Assay Reverse Transcription Multiplex Ligation-dependent Probe Amplification is high
throughput assay, which can rapidly profile mRNA expression of host. Leiden University Medical Center,
T.Ottenhoff (T.H.M.Ottenhoff@lumc.nl)
Multiplex detection of cytokine and chemokine biomarkers: evaluate the production of
cell signaling proteins, such as cytokines, chemokines, and inflammatory biomarkers in multiple samples, using
the Bio-Plex suspension array system University of Siena, A Ciabattini (annalisa.ciabattini@unisi.it)
Formulation of vaccine antigens onto biodegradable particles: Formulate sub-unit or
vaccine components onto biodegradable particles, containing or not in their core, different immunemodulators, such as TLR or Nod ligands, by using passive adsorption process onto Poly Lactic Acid (PLA)
particles of 150<x<200nm size. CNRS, B Verrier. (bernard.verrier@ibcp.fr)
Systems biology analysis and mathematical modeling: Construction, simulation and
identification of stochastic and deterministic dynamical mathematical models of adaptive immune response in
animal models. Statistical analysis of experimental data (probability distribution function estimation,
classification, etc.). Interference of gene regulation networks. Università di Siena – Dipartimento di Ingegneria
dell’Informazione e Scienze Matematiche, Antonio Vicino (vicino@ing.unisi.it)
High-dimensional single cell characterization of the innate and adaptive response
by CyTOF: Our laboratory established an innate and an adaptive antibody panel which are currently used to
characterize immune responses in humans and NHP allowing for the deep exploration of the innate and
adaptive immune response. The adaptive panel includes the detection of markers such as CD3, CD4 and CD8 to
determine cell phenotype; CD45RA, CCR7, CD28 and CD95 to determine differentiation stages; IFN-γ, TNF-α, IL2, MIP-1β, CD154, CD137 to characterize T-cell function and several other markers to address the proliferative
and cytotoxic capacity of the cells. The innate panel includes the detection of CD66, CD3, CD14, CD20, HLA-DR,
CD11c, and CD123, to determine the cell phenotype together with antibody directed to cytokines, chemokines,
TLR ligands, Fc receptors and activation markers. More than 100 different antibody clone /metal tag clones
combinations were already tested and we have the capacity to establish a new antibody panel in around three
months.
Offer available for Public Health Organizations Only:
New Vaccination Recommendations for the 50+ Generation Coordinate a study to gain
knowledge about the levels of protection against vaccine-preventable diseases in different adult age groups
and in different European member states and offer consultation about improved vaccination strategies.
Institute for Biomedical Aging Research, Institute in Innsbruck, Beatrix Grubeck-Loebenstein.
(beatrix.grubeck@uibk.ac.at)
Evaluation of licensed vaccines in the elderly We offer to conduct clinical studies enrolling
healthy volunteers aged 50-100 years in order to evaluate humoral and cellular immune responses against
antigens of licensed vaccines. In addition to biological parameters vaccination history will be assessed in detail.
Upon request we will design study protocols, conduct the clinical trial (regulatory documents, enrollment of
participants, vaccination and sample collection etc.), perform laboratory analysis of humoral and cellular
immune responses and data analysis. Institute for Biomedical Aging Research, Institute in Innsbruck, Beatrix
Grubeck-Loebenstein. (beatrix.grubeck@uibk.ac.at)
Description of laboratory Please describe your laboratory and its associated facilities in relation to this
request
Relevant Publications Please list here your publications (with d.o.i) relevant to your application maximum 5 –
1.
2.
3.
4.
5.
ADITEC Project: Sclavo Vaccines Association Siena Italy Email: info@sclavo.org
http://www.aditecproject.eu/home.html